



ASX ANNOUNCEMENT

28 September 2020

NOTICE OF DATE OF FORTHCOMING AGM & OTHER RELEVANT DATES

28 September 2020 – Pursuant to ASX Listing Rule 3.13.1, Cann Group Limited (ASX:CAN) (the **Company**) is pleased to advise the following details in relation to the Company's forthcoming Annual General Meeting (**AGM**), which will be held by way of a virtual meeting:

- Date and time for AGM: Tuesday, 24 November 2020 at 10.00am
- Date of Notice of Meeting dispatch: Friday, 23 October 2020
- Last date for receipt of nominations as a director: Monday, 5 October 2020

Further details in relation to the AGM, including items of business to be voted upon by shareholders, and instructions on how shareholders may attend and vote at the meeting, will be provided in the Notice of Meeting.

The Company's Annual Report, which includes the Remuneration Report, was lodged with ASX on 27 August 2020 and sent to shareholders on that date. It can be accessed and downloaded from the Company's website [here](#) and shareholders can obtain a hard copy by emailing a request to the Company at contact@canngrouplimited.com.

The Company looks forward to shareholders participating at this year's AGM.

Authorised for release by Geraldine Farrell, Company Secretary, Cann Group Limited.

For further information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 498 000 762
clive.fanning@canngrouplimited.com

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. The company has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation facility near Mildura, Victoria. The Company has executed collaboration agreements that have enabled it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products. **Learn more at www.canngrouplimited.com**